Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement.

Tabernero J, Shapiro GI, LoRusso PM, Cervantes A, Schwartz GK, Weiss GJ, Paz-Ares L, Cho DC, Infante JR, Alsina M, Gounder MM, Falzone R, Harrop J, White AC, Toudjarska I, Bumcrot D, Meyers RE, Hinkle G, Svrzikapa N, Hutabarat RM, Clausen VA, Cehelsky J, Nochur SV, Gamba-Vitalo C, Vaishnaw AK, Sah DW, Gollob JA, Burris HA 3rd.

Cancer Discov. 2013 Apr;3(4):406-17. doi: 10.1158/2159-8290.CD-12-0429. Epub 2013 Jan 28.

2.

Safety profile of RNAi nanomedicines.

Barros SA, Gollob JA.

Adv Drug Deliv Rev. 2012 Dec;64(15):1730-7. doi: 10.1016/j.addr.2012.06.007. Epub 2012 Jun 22. Review.

PMID:
22732527
3.

Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice.

Judge AD, Robbins M, Tavakoli I, Levi J, Hu L, Fronda A, Ambegia E, McClintock K, MacLachlan I.

J Clin Invest. 2009 Mar;119(3):661-73. doi: 10.1172/JCI37515. Epub 2009 Feb 23.

4.
5.

Direct Pharmacological Inhibition of β-Catenin by RNA Interference in Tumors of Diverse Origin.

Ganesh S, Koser ML, Cyr WA, Chopda GR, Tao J, Shui X, Ying B, Chen D, Pandya P, Chipumuro E, Siddiquee Z, Craig K, Lai C, Dudek H, Monga SP, Wang W, Brown BD, Abrams MT.

Mol Cancer Ther. 2016 Sep;15(9):2143-54. doi: 10.1158/1535-7163.MCT-16-0309. Epub 2016 Jul 7.

6.

Knockdown of β-catenin with dicer-substrate siRNAs reduces liver tumor burden in vivo.

Dudek H, Wong DH, Arvan R, Shah A, Wortham K, Ying B, Diwanji R, Zhou W, Holmes B, Yang H, Cyr WA, Zhou Y, Shah A, Farkiwala R, Lee M, Li Y, Rettig GR, Collingwood MA, Basu SK, Behlke MA, Brown BD.

Mol Ther. 2014 Jan;22(1):92-101. doi: 10.1038/mt.2013.233. Epub 2013 Oct 3.

7.

Intravesical delivery of small activating RNA formulated into lipid nanoparticles inhibits orthotopic bladder tumor growth.

Kang MR, Yang G, Place RF, Charisse K, Epstein-Barash H, Manoharan M, Li LC.

Cancer Res. 2012 Oct 1;72(19):5069-79. doi: 10.1158/0008-5472.CAN-12-1871. Epub 2012 Aug 6.

8.

Direct cytosolic siRNA delivery by reconstituted high density lipoprotein for target-specific therapy of tumor angiogenesis.

Ding Y, Wang Y, Zhou J, Gu X, Wang W, Liu C, Bao X, Wang C, Li Y, Zhang Q.

Biomaterials. 2014 Aug;35(25):7214-27. doi: 10.1016/j.biomaterials.2014.05.009. Epub 2014 May 27.

PMID:
24875759
9.

Kinesin spindle protein SiRNA slows tumor progression.

Marra E, Palombo F, Ciliberto G, Aurisicchio L.

J Cell Physiol. 2013 Jan;228(1):58-64. doi: 10.1002/jcp.24103.

PMID:
22552964
10.

Lentivirus-mediated shRNA interference targeting vascular endothelial growth factor inhibits angiogenesis and progression of human pancreatic carcinoma.

Zhao X, Zhu DM, Gan WJ, Li Z, Zhang JL, Zhao H, Zhou J, Li DC.

Oncol Rep. 2013 Mar;29(3):1019-26. doi: 10.3892/or.2012.2203. Epub 2012 Dec 19.

PMID:
23254994
11.

Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles.

Davis ME, Zuckerman JE, Choi CH, Seligson D, Tolcher A, Alabi CA, Yen Y, Heidel JD, Ribas A.

Nature. 2010 Apr 15;464(7291):1067-70. doi: 10.1038/nature08956. Epub 2010 Mar 21.

12.

RNAi-mediated gene silencing in non-human primates.

Zimmermann TS, Lee AC, Akinc A, Bramlage B, Bumcrot D, Fedoruk MN, Harborth J, Heyes JA, Jeffs LB, John M, Judge AD, Lam K, McClintock K, Nechev LV, Palmer LR, Racie T, Röhl I, Seiffert S, Shanmugam S, Sood V, Soutschek J, Toudjarska I, Wheat AJ, Yaworski E, Zedalis W, Koteliansky V, Manoharan M, Vornlocher HP, MacLachlan I.

Nature. 2006 May 4;441(7089):111-4. Epub 2006 Mar 26.

PMID:
16565705
13.

Oral delivery of shRNA and siRNA via multifunctional polymeric nanoparticles for synergistic cancer therapy.

Han L, Tang C, Yin C.

Biomaterials. 2014 May;35(15):4589-600. doi: 10.1016/j.biomaterials.2014.02.027. Epub 2014 Mar 6.

PMID:
24613049
14.

Lipid nanoparticles for short interfering RNA delivery.

Leung AK, Tam YY, Cullis PR.

Adv Genet. 2014;88:71-110. doi: 10.1016/B978-0-12-800148-6.00004-3. Review.

PMID:
25409604
15.

Polyethylenimine/small interfering RNA-mediated knockdown of vascular endothelial growth factor in vivo exerts anti-tumor effects synergistically with Bevacizumab.

Höbel S, Koburger I, John M, Czubayko F, Hadwiger P, Vornlocher HP, Aigner A.

J Gene Med. 2010 Mar;12(3):287-300. doi: 10.1002/jgm.1431.

PMID:
20052738
16.

Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs.

Soutschek J, Akinc A, Bramlage B, Charisse K, Constien R, Donoghue M, Elbashir S, Geick A, Hadwiger P, Harborth J, John M, Kesavan V, Lavine G, Pandey RK, Racie T, Rajeev KG, Röhl I, Toudjarska I, Wang G, Wuschko S, Bumcrot D, Koteliansky V, Limmer S, Manoharan M, Vornlocher HP.

Nature. 2004 Nov 11;432(7014):173-8.

17.

Harnessing RNAi-based nanomedicines for therapeutic gene silencing in B-cell malignancies.

Weinstein S, Toker IA, Emmanuel R, Ramishetti S, Hazan-Halevy I, Rosenblum D, Goldsmith M, Abraham A, Benjamini O, Bairey O, Raanani P, Nagler A, Lieberman J, Peer D.

Proc Natl Acad Sci U S A. 2016 Jan 5;113(1):E16-22. doi: 10.1073/pnas.1519273113. Epub 2015 Dec 23.

18.

Rolling circle transcription-based polymeric siRNA nanoparticles for tumor-targeted delivery.

Lee JH, Ku SH, Kim MJ, Lee SJ, Kim HC, Kim K, Kim SH, Kwon IC.

J Control Release. 2017 Oct 10;263:29-38. doi: 10.1016/j.jconrel.2017.03.390. Epub 2017 Mar 31.

PMID:
28373128
19.

Development of siRNA payloads to target KRAS-mutant cancer.

Yuan TL, Fellmann C, Lee CS, Ritchie CD, Thapar V, Lee LC, Hsu DJ, Grace D, Carver JO, Zuber J, Luo J, McCormick F, Lowe SW.

Cancer Discov. 2014 Oct;4(10):1182-1197. doi: 10.1158/2159-8290.CD-13-0900. Epub 2014 Aug 6.

20.

A study of the suppressive effect on human pancreatic adenocarcinoma cell proliferation and angiogenesis by stable plasmid-based siRNA silencing of c-Src gene expression.

Zhao X, Li DC, Zhao H, Li Z, Wang JX, Zhu DM, Zhou J, Cen JN.

Oncol Rep. 2012 Mar;27(3):628-36. doi: 10.3892/or.2011.1602. Epub 2011 Dec 21.

PMID:
22200682

Supplemental Content

Support Center